Q2 2025 · 13F-HR
BML Capital Management, LLCholdings as filed
Filed 2025-08-11 · accession 0001754960-25-000555
$132.2M
Reported value
24
Positions
2025-06-30
Period end
The Brief · BML Capital Management, LLC · Q2 2025
AI · grounded in 13F
BML Capital Management, LLC established a new position in AVIR valued at $27.4M. The fund also initiated new stakes in THIRD HARMONIC BIO INC for $20.8M and ACRS for $20.2M. Additional new positions include TIL at $11.1M and EPIEUR at $7.2M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $27.4M | 20.7% | 7,609,812 | Common | NONE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $20.8M | 15.7% | 3,824,417 | Common | NONE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $20.2M | 15.3% | 14,250,000 | Common | NONE |
| 45783C200 | TIL | INSTIL BIO INC | $11.1M | 8.43% | 534,899 | Common | NONE |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $7.2M | 5.43% | 4,221,546 | Common | NONE |
| 68403P203 | ORMP | ORAMED PHARMACEUTICALS INC | $6.9M | 5.25% | 3,083,253 | Common | NONE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $6.6M | 4.97% | 3,057,526 | Common | NONE |
| 45175G108 | — | IKENA ONCOLOGY INC | $5.4M | 4.09% | 4,030,102 | Common | NONE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $5.3M | 4.01% | 5,000,000 | Common | NONE |
| 022307102 | ALMS | ALUMIS INC | $3.6M | 2.75% | 1,210,415 | Common | NONE |
| 49372L209 | 2KZ0 | KEZAR LIFE SCIENCES INC | $2.9M | 2.20% | 635,183 | Common | NONE |
| N51517105 | 4PKB | LAVA THERAPEUTICS NV | $2.6M | 1.97% | 1,970,610 | Common | NONE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $2.2M | 1.67% | 1,136,091 | Common | NONE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $2.2M | 1.64% | 5,890,434 | Common | NONE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $1.8M | 1.35% | 1,821,558 | Common | NONE |
| 88160R101 | TSLA | TESLA INC | $1.7M | 1.25% | 200 | PUT | NONE |
| 046484309 | ASTC | ASTROTECH CORP | $1.3M | 0.96% | 220,410 | Common | NONE |
| 04746L104 | — | ATHIRA PHARMA INC | $975,661 | 0.74% | 3,230,667 | Common | NONE |
| 128058302 | LSTA | LISATA THERAPEUTICS INC | $608,272 | 0.46% | 209,814 | Common | NONE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $475,064 | 0.36% | 118,766 | Common | NONE |
| 90042W100 | — | TURNSTONE BIOLOGICS CORP | $396,116 | 0.30% | 1,103,386 | Common | NONE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $300,000 | 0.23% | 150,000 | Common | NONE |
| 43157M102 | — | HILLEVAX INC | $182,907 | 0.14% | 91,913 | Common | NONE |
| 92511W108 | VRCA | VERRICA PHARMACEUTICALS INC | $92,583 | 0.07% | 174,651 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.